At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

NEW YORK – Arrowhead Pharmaceuticals on Monday said it has treated the first patients with ARO-ALK7, an RNAi therapeutic that the company is developing for obesity, within a first-in-human Phase I/IIa ...